Nifedipine Impact on Adrenal Hyperplasia and Glucocorticoid Reduction

This study focuses on Congenital Adrenal Hyperplasia (CAH), a condition affecting the adrenal glands. The main goal is to explore the effects of a medication called nifedipine, a calcium channel antagonist, on the body's adrenal system in patients with CAH. The study is important as it could potentially lead to a reduction in the dosage of glucocorticoid, a common treatment for CAH, which often comes with unwanted side effects. This research aims to improve the care and treatment options for individuals living with CAH. The study is divided into two phases and follows a double-blind, placebo-controlled design. In Phase I, the study will examine if nifedipine can decrease the levels of adrenocorticotropic hormone (ACTH) more effectively than a placebo, and assess the dose-dependency of nifedipine's effects. Phase II aims to evaluate the long-term effects of nifedipine, specifically whether it can help reduce the amount of glucocorticoid needed to manage the condition. Throughout the study, the effects of the medication will be carefully monitored to ensure safety and effectiveness.